SCHEMBL6301694

SCHEMBL6301694

O=C(O)CN1CCN(c2ccccc2)CC1

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.72
ALDH1A1 P00352 2/20 0.72
HTR1A P08908 1/20 0.58
HTR7 P34969 1/20 0.58
CHRNA7 P36544 1/20 0.58
S1PR1 P21453 1/20 0.57
GFER P55789 1/20 0.57
POLB P06746 1/20 0.57
USP2 O75604 1/20 0.57
ALOX15 P16050 1/20 0.57
TSHR P16473 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
DRD4 P21917 1/20 0.56
KCNH2 Q12809 1/20 0.56
PKM P14618 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
ATM Q13315 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1374296 0.98 MAPT (0.70) MAPTALDH1A1HTR1AHTR7CHRNA7
SCHEMBL13780698 0.90 GAA (0.63) MAPTALDH1A1S1PR1POLBUSP2
SCHEMBL13234976 0.85 MAPT (0.67) MAPTALDH1A1HTR1AS1PR1POLB
SCHEMBL4172008 0.85 MAPT (0.68) MAPTALDH1A1HTR1AHTR7CHRNA7
SCHEMBL3709528 0.85 MAPT (0.68) MAPTALDH1A1HTR1AHTR7CHRNA7
SCHEMBL4172010 0.85 MAPT (0.68) MAPTALDH1A1HTR1AHTR7CHRNA7
SCHEMBL2881604 0.84 MAPT (0.66) MAPTALDH1A1HTR1AS1PR1POLB
SCHEMBL20271722 0.84 SMN1; SMN2 (0.68) MAPTALDH1A1HTR1AHTR7S1PR1
SCHEMBL5114345 0.84 REV1 (0.65) MAPTALDH1A1HTR1AS1PR1ALOX15
SCHEMBL13723844 0.84 MAPT (0.59) MAPTALDH1A1S1PR1GFERPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260076982-A1 Prodrugs of Cannbidiol [CBD]-Type Phytocannabinoids and a Process for Preparation Thereof COUNCIL SCIENT IND RES (IN) 2026-03-19 US disclosed
EP-4551241-A1 PRODRUGS OF CANNBIDIOL [CBD]-TYPE PHYTOCANNABINOIDS AND A PROCESS FOR PREPARATION THEREOF Council of Scientific & Industrial Research (IN) 2025-05-14 EP disclosed
WO-2024009324-A1 PRODRUGS OF CANNBIDIOL [CBD]-TYPE PHYTOCANNABINOIDS AND A PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2024-01-11 WO disclosed
WO-2024009324-A1 PRODRUGS OF CANNBIDIOL [CBD]-TYPE PHYTOCANNABINOIDS AND A PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2024-01-11 WO disclosed
US-6869957-B1 Non-peptide tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2005-03-22 US disclosed
US-6727255-B1 BRAIN, NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS ELI LILLY AND COMPANY 2004-04-27 US disclosed
US-6596724-B2 Used in promoting weight loss and treating eating disorders BRISTOL-MYERS SQUIBB COMPANY 2003-07-22 US disclosed
EP-0699665-B1 Imidazoline derivatives, their preparation and their use as tachykinin receptor antagonists LILLY CO ELI (US) 2003-03-05 EP disclosed
EP-0729468-B1 NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2003-01-15 EP disclosed
US-6403577-B1 Hexamethyleneiminyl tachykinin receptor antagonists ELI LILLY AND COMPANY 2002-06-11 US disclosed
EP-0729468-A1 NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 1996-09-04 EP disclosed
EP-0729468-A4 NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS LILLY CO ELI (US) 1996-07-12 EP disclosed
EP-0699665-A1 Imidazoline derivatives, their preparation and their use as tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 1996-03-06 EP disclosed
EP-0699674-A1 1-Aryl-2-acetylamidopentanone derivatives for use as tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 1996-03-06 EP disclosed
EP-0686629-A2 Cyclohexyl tachykinine receptor antagonists ELI LILLY AND COMPANY (US) 1995-12-13 EP disclosed
WO-1995014017-A1 NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 1995-05-26 WO disclosed
US-5378690-A Treatment of angiotensin induced hypertension SANKYO COMPANY, LIMITED (JP) 1995-01-03 US disclosed
EP-0274259-B1 New renin-inhibitory oligopeptides, their preparaton and their use SANKYO CO (JP) 1994-02-16 EP disclosed
EP-0274259-A2 New renin-inhibitory oligopeptides, their preparaton and their use Sankyo Company Limited (JP) 1988-07-13 EP disclosed
US-4593027-A 3-aryl-7-chloro-3,4-dihydroacridine-1,9(2H,10H)-dione 1-oximes and 1-hydrazone derivatives, their salts, a process for their preparation, agents containing them and their use HOECHST AKTIENGESELLSCHAFT (DE) 1986-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260076982-A1 Prodrugs of Cannbidiol [CBD]-Type Phytocannabinoids and a Process for Preparation Thereof CNR1, CNR2, CBR1 MAPT 3826/4885ALDH1A1 1408/4885HTR1A 174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.